AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
AtriCure has announced its preliminary financial results for Q4 and full year 2024, alongside its 2025 financial guidance.
Preliminary, unaudited revenue for Q4 2024 is expected to be $124.3 million, a growth of approximately 17% over Q4 2023. U.S. revenue is projected at $101.6 million (14% growth), and international revenue at $22.7 million (28% growth). This growth is driven by strong performance in cryoSPHERE® devices, AtriClip® devices, and the EnCompass® clamp.
For the full year 2024, revenue is expected to be $465.3 million, up by 17% from 2023. Adjusted EBITDA is anticipated to be around $26 million to $29 million, with an adjusted loss per share of $0.74 to $0.80.
Looking ahead, AtriCure projects 2025 revenue between $517 million and $527 million, with positive adjusted EBITDA of $40 million to $44 million and modest cash flow generation. The company will host an Analyst & Investor Day on March 26, 2025, to discuss its product portfolio, innovative pipeline, and long-term financial goals.
AtriCure ha annunciato i suoi risultati finanziari preliminari per il quarto trimestre e l'intero anno 2024, insieme alle previsioni finanziarie per il 2025.
Le entrate preliminari e non verificate per il quarto trimestre 2024 sono previste essere di 124,3 milioni di dollari, un aumento di circa il 17% rispetto al quarto trimestre 2023. Le entrate negli Stati Uniti sono stimate a 101,6 milioni di dollari (crescita del 14%), mentre le entrate internazionali si attestano a 22,7 milioni di dollari (crescita del 28%). Questa crescita è guidata dalle solide prestazioni dei dispositivi cryoSPHERE®, dei dispositivi AtriClip® e della pinza EnCompass®.
Per l'intero anno 2024, le entrate sono previste essere di 465,3 milioni di dollari, con un aumento del 17% rispetto al 2023. Si prevede un EBITDA rettificato di circa 26 milioni a 29 milioni di dollari, con una perdita rettificata per azione compresa tra 0,74 e 0,80 dollari.
Guardando avanti, AtriCure prevede entrate per il 2025 comprese tra 517 milioni e 527 milioni di dollari, con un EBITDA rettificato positivo tra 40 milioni e 44 milioni di dollari e una generazione di flusso di cassa modesta. L'azienda ospiterà un Analyst & Investor Day il 26 marzo 2025 per discutere del suo portafoglio prodotti, della pipeline innovativa e degli obiettivi finanziari a lungo termine.
AtriCure ha anunciado sus resultados financieros preliminares para el cuarto trimestre y el año completo 2024, junto con sus previsiones financieras para 2025.
Se espera que los ingresos preliminares no auditados para el cuarto trimestre de 2024 sean de 124,3 millones de dólares, un crecimiento de aproximadamente el 17% en comparación con el cuarto trimestre de 2023. Los ingresos en EE.UU. se proyectan en 101,6 millones de dólares (crecimiento del 14%), mientras que los ingresos internacionales alcanzan 22,7 millones de dólares (crecimiento del 28%). Este crecimiento es impulsado por un sólido rendimiento en los dispositivos cryoSPHERE®, los dispositivos AtriClip® y la pinza EnCompass®.
Para el año completo 2024, se espera que los ingresos sean de 465,3 millones de dólares, un aumento del 17% en comparación con 2023. Se anticipa un EBITDA ajustado de aproximadamente 26 millones a 29 millones de dólares, con una pérdida ajustada por acción de 0,74 a 0,80 dólares.
De cara al futuro, AtriCure proyecta ingresos para 2025 entre 517 millones y 527 millones de dólares, con un EBITDA ajustado positivo de 40 millones a 44 millones de dólares y una generación modesta de flujo de caja. La compañía llevará a cabo un Analyst & Investor Day el 26 de marzo de 2025 para discutir su portafolio de productos, su pipeline innovador y sus objetivos financieros a largo plazo.
AtriCure는 2024년 4분기 및 전체 연도에 대한 예비 재무 결과와 2025년 재무 안내를 발표했습니다.
2024년 4분기 예비 미감사 수익은 1억 2,430만 달러로 예상되며, 이는 2023년 4분기 대비 약 17% 증가한 수치입니다. 미국 수익은 1억 1,600만 달러로 예상되며(14% 성장) 국제 수익은 2,270만 달러로 예상됩니다(28% 성장). 이러한 성장은 cryoSPHERE® 장치, AtriClip® 장치 및 EnCompass® 클램프의 강력한 성과에 의해 주도되고 있습니다.
2024년 전체 연도 수익은 4억 6,530만 달러로 예상되며, 이는 2023년 대비 17% 증가한 것입니다. 조정 EBITDA는 약 2,600만 달러에서 2,900만 달러로 예상되며, 조정 주당 손실은 0.74에서 0.80달러로 예상됩니다.
앞으로 AtriCure는 2025년 수익을 5억 1,700만 달러에서 5억 2,700만 달러로 전망하고 있으며, 조정 EBITDA는 4천만 달러에서 4,400만 달러로 긍정적인 수치를 기대하고 있으며, 소규모 현금 흐름 생성이 예상됩니다. 이 회사는 2025년 3월 26일에 Analyst & Investor Day를 개최하여 제품 포트폴리오, 혁신적 파이프라인 및 장기 재무 목표를 논의할 것입니다.
AtriCure a annoncé ses résultats financiers préliminaires pour le quatrième trimestre et l'année complète 2024, ainsi que ses prévisions financières pour 2025.
Les revenus préliminaires non audités pour le quatrième trimestre 2024 devraient atteindre 124,3 millions de dollars, soit une croissance d'environ 17 % par rapport au quatrième trimestre 2023. Les revenus aux États-Unis sont projetés à 101,6 millions de dollars (croissance de 14 %), et les revenus internationaux à 22,7 millions de dollars (croissance de 28 %). Cette croissance est soutenue par de solides performances des dispositifs cryoSPHERE®, des dispositifs AtriClip® et de la pince EnCompass®.
Pour l'année complète 2024, les revenus devraient atteindre 465,3 millions de dollars, en hausse de 17 % par rapport à 2023. Un EBITDA ajusté d'environ 26 millions à 29 millions de dollars est prévu, avec une perte ajustée par action de 0,74 à 0,80 dollar.
Pour 2025, AtriCure prévoit des revenus compris entre 517 millions et 527 millions de dollars, avec un EBITDA ajusté positif de 40 millions à 44 millions de dollars et une génération de flux de trésorerie modeste. L'entreprise tiendra un Analyst & Investor Day le 26 mars 2025 pour discuter de son portefeuille de produits, de sa pipeline innovante et de ses objectifs financiers à long terme.
AtriCure hat seine vorläufigen finanziellen Ergebnisse für das 4. Quartal und das gesamte Jahr 2024 sowie die finanziellen Prognosen für 2025 bekannt gegeben.
Der vorläufige, ungeprüfte Umsatz für das 4. Quartal 2024 wird auf 124,3 Millionen Dollar geschätzt, was einem Wachstum von etwa 17% gegenüber dem 4. Quartal 2023 entspricht. Der Umsatz in den USA wird mit 101,6 Millionen Dollar (14% Wachstum) und der internationale Umsatz mit 22,7 Millionen Dollar (28% Wachstum) prognostiziert. Dieses Wachstum wird durch die starken Leistungen der cryoSPHERE®-Geräte, der AtriClip®-Geräte und der EnCompass®-Klemme angetrieben.
Für das gesamte Jahr 2024 wird ein Umsatz von 465,3 Millionen Dollar erwartet, was einem Anstieg von 17% im Vergleich zu 2023 entspricht. Das bereinigte EBITDA wird voraussichtlich bei etwa 26 Millionen bis 29 Millionen Dollar liegen, mit einem bereinigten Verlust pro Aktie von 0,74 bis 0,80 Dollar.
Für 2025 prognostiziert AtriCure Umsätze zwischen 517 Millionen und 527 Millionen Dollar, mit einem positiven bereinigten EBITDA von 40 Millionen bis 44 Millionen Dollar und moderater Cashflow-Generierung. Das Unternehmen wird am 26. März 2025 einen Analysten- und Investoren-Tag veranstalten, um sein Produktportfolio, die innovative Pipeline und die langfristigen finanziellen Ziele zu erörtern.
- Q4 2024 revenue expected to be $124.3 million, a 17% growth.
- Full year 2024 revenue projected at $465.3 million, a 17% increase.
- 2025 revenue guidance between $517 million and $527 million.
- Positive adjusted EBITDA for 2024 expected between $26 million and $29 million.
- 2025 adjusted EBITDA projected at $40 million to $44 million.
- Expected adjusted loss per share for 2024 is $0.74 to $0.80.
Insights
AtriCure's preliminary Q4 2024 results showcase robust performance with revenue reaching
The 2025 guidance of
Key growth drivers include cryoSPHERE® devices, AtriClip® in open chest procedures and the EnCompass® clamp, though headwinds persist in the U.S. Hybrid franchise. The diversified product portfolio helps mitigate segment-specific challenges while maintaining overall growth momentum.
The product mix driving AtriCure's growth reflects strategic positioning in high-value medical device segments. The strong performance of cryoSPHERE® devices indicates growing adoption in pain management applications, while AtriClip's® momentum in open chest procedures suggests expanding market share in the LAA management space, where AtriCure maintains market leadership.
The company's innovation pipeline and product portfolio diversification across Afib treatment, LAA management and post-operative pain management creates multiple revenue streams. This multi-pronged approach helps maintain growth despite localized challenges in specific segments like the U.S. Hybrid franchise. The upcoming Analyst & Investor Day will likely showcase new innovations and market expansion strategies, potentially revealing new growth catalysts.
Preliminary, unaudited revenue for fourth quarter 2024 is expected to be
Preliminary, unaudited revenue for full year 2024 is expected to be
“2024 was another year of remarkable growth and innovation for AtriCure. We introduced several new products, expanded the reach of our franchises, and continued to deliver best-in-class solutions for providers and patients around the world,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We expect overall momentum of our business to continue in 2025 despite ongoing pressure in our
2025 Financial Guidance
Management projects 2025 revenue of approximately
Analyst and Investor Day
AtriCure will host an Analyst & Investor Day at its headquarters in
“Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expansion at our Analyst and Investor Day. We also look forward to bringing perspectives from key opinion leaders as well as sharing longer-term financial goals as we continue driving growth and expanded profitability,” said Michael Carrel, President and Chief Executive Officer of AtriCure.
A webcast of the presentation and Q&A sessions will be available on the “Investors” section of the company’s website at https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide1. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly known as Twitter) @AtriCure.
Forward-Looking Statements
This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of January 13, 2025. We assume no obligation to update any forward-looking statements contained in this release and the related attachment as a result of new information or future events or developments, except as may be required by law.
1 Linz, D., Gawalko, M., Betz, K., Hendriks, J. M., Lip, G. Y., Vinter, N., Guo, Y. & Johnsen, S. (2024). Atrial fibrillation: epidemiology, screening and digital health. The Lancet Regional Health–Europe, Volume 37, 100786, February 2024 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113069942/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
(415) 937-5402
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
What are AtriCure's Q4 2024 preliminary revenue results?
What is AtriCure's full year 2024 revenue expectation?
What is the projected 2025 revenue for AtriCure?
What is AtriCure's adjusted EBITDA guidance for 2025?
When is AtriCure's Analyst & Investor Day scheduled?
What is AtriCure's expected adjusted loss per share for 2024?
